FDA panel votes 3-14 that Abbott (ABT) has not found right Humira dose
FDA panel votes 3-14 that Abbott (NYSE: ABT) has not found right Humira dose.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- In Specialty Pharma, Short Interst in Abbott (ABT), Endo (ENDP) and Valeant (VRX) Surge
- Genomic Health (GHDX) Announces Publication of Positive Oncotype DX Data in ASCO Journal
- Shire Plc (SHPG): '607 Data Could Shore Up Eye Franchise - Leerink
Create E-mail Alert Related CategoriesFDA, General News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!